^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Glioblastoma
    Drug:Avastin (bevacizumab) (VEGF-A inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    FDA
    Published date:
    02/26/2004
    Excerpt:
    Avastin is a vascular endothelial growth factor inhibitor indicated for the treatment of...Recurrent glioblastoma in adults.
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    ADULT GLIOMA: GLIOBLASTOMA….Adjuvant Treatment, KPS ≥60...Other Recommended Regimens...Systemic therapy + bevacizumab...Carmustine or lomustine + bevacizumab...TMZ + bevacizumab
    Secondary therapy:
    lomustine; temozolomide; carmustine
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Glioblastoma...Preferred Regimens...Bevacizumab.
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    ASCO.org
    Excerpt:
    CONTRADICTING EVIDENCE: The panel does not recommend the routine addition of bevacizumab to standard therapy for newly diagnosed glioblastoma outside a clinical trial (Strong recommendation).
    Secondary therapy:
    temozolomide
    Evidence Level:
    Sensitive: B - Late Trials
    New
    Source:
    N Engl J Med
    Title:

    Lomustine and Bevacizumab in Progressive Glioblastoma

    Excerpt:
    We randomly assigned patients with progression after chemoradiation in a 2:1 ratio to receive lomustine plus bevacizumab (combination group, 288 patients) or lomustine alone (monotherapy group, 149 patients)….Locally assessed progression-free survival was 2.7 months longer in the combination group than in the monotherapy group: 4.2 months versus 1.5 months (hazard ratio for disease progression or death, 0.49; 95% CI, 0.39 to 0.61; P<0.001).
    Secondary therapy:
    lomustine
    DOI:
    10.1056/NEJMoa1707358
    Trial ID:
    EORTC 26101